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Rhesus monkeys were trained to discriminate saline from an injection of ketamine. In tests of stimulus generaliza- 
tion, phencyclidine (PCP) produced dose-related ketamine-appropriate responding in each monkey. Two monohydrox- 
ylated PCP metabolites also produced ketamine-like discriminative effects, although only at considerably higher doses 
than did PCP. A third monohydroxylated PCP metabolite produced only sham-appropriate responding. The results 
suggest that these PCP metabolites contribute little to the behavioral actions of PCP in the monkey. 
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1. Introduction 
Phencyclidine (PCP) was developed as an 
anesthetic agent but was withdrawn from clinical 
use because of disturbing side-effects, such as 
drunkenness, mental impairment, and psycho- 
tomimetic phenomena (Domino, 1964). More re- 
cently, a long-lasting toxic psychosis has been 
observed following single high doses of PCP (e.g., 
Luisada, 1978). PCP has been detected both in the 
brain and in urinary excretion for at least several 
days following its administration (e.g., Misra et al., 
1979). It is of interest, therefore, to evaluate the 
effects of these proposed metabolites to determine 
* Present address: Addiction Research Center, National In- 
stitute on Drug Abuse, P.O. Box 12390, Lexington, KY 
40583, U.S.A. 
** To whom all correspondence should be addressed: Depart- 
ment  of Pharmacology, M6322 Medical Science I Building, 
University of Michigan Medical School, Ann Arbor, 
Michigan 48109, U.S.A. 
0014-2999/82/0000-0000/$02.75 © 1982 Elsevier Biomedical Press 
whether they contribute to the overall spectrum of 
effects produced by PCP. 
Various monohydroxylated PCP metabo- 
lites, including 4-phenyl-4-piperidinocyclohexanol 
(PPC) and 1-(1-phenylcylohexyl)-4-hydroxy-piper- 
idine (PCHP) have been identified in a number of 
species (for review, see Jasinski et al., 1981). The 
present experiment evaluated the capacity of PPC 
and PCHP to produce discriminative stimulus ef- 
fects similar to ketamine, a compound closely re- 
lated to PCP in structure and pharmacologic activ- 
ity, in rhesus monkeys. A third monohydroxylated 
PCP metabolite, 1-[1-(4-hydroxyphenyl)-cyclo- 
hexanol]-piperidine (HPCP) (Domino, personal 
communications) was also evaluated. The dis- 
criminative stimulus effects of ketamine in rhesus 
monkeys are shared by PCP but not by a number 
of drugs from other pharmacological classes 
(Solomon et al., unpublished observations). Thus, 
this procedure appears to be an appropriate assay 
for evaluating PCP-like discriminative stimulus ef- 
fects. The time course of the discriminative control 
of behavior exerted by ketamine and by PCP were 
also studied in the present experiment. 
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2. Materials and methods 
The subjects were three rhesus monkeys 
(Macaca mulatta) (754, 794 and 808) that had 
participated in a previous study of the discrimina- 
tive effects of ketamine (Solomon et al., unpub- 
lished observations). The monkeys were main- 
tained at 80% of their free-feeding weights. Each 
experimental chamber contained two response 
levers, a food receptacle, and an array of colored 
7-W stimulus lights. Continuous ventilation and 
masking noise were provided by an exhaust fan 
and a speaker. Banana-flavored food pellets were 
delivered to the food receptacle by a pellet dis- 
penser mounted outside the chamber. Program- 
ming and recording of experimental sessions were 
accomplished with a computer and cumulative 
recorders. 
The procedure has been described in detail 
previously (Solomon et al., unpublished observa- 
tions). Daily training sessions consisted of a series 
of discrete trials, each preceded by a 10 min 
blackout period which was initiated by either a 
sham injection or a s.c. injection of ketamine (1.0 
or 1.8 mg/kg) .  In each trial, 100 consecutive re- 
sponses on the correct lever (e.g., the right lever 
after sham and the left lever after ketamine) pro- 
duced food. Each trial ended after 5 min, whether 
or not food had been delivered. Training sessions 
began with 0-4 sham trials and ended after 2 
ketamine trials. Ketamine was administered prior 
to the first ketamine trial; the second ketamine 
trial was preceded by a sham injection. A dis- 
crimination was considered to be established when 
a monkey emitted at least 90% correct responses in 
every trial during five consecutive sessions. 
In test sessions, each trial was preceded by a s.c. 
drug injection of the test compound which in- 
creased the total dose injected within the session 
by 1 /4  or 1/2  log-unit steps. During each trial of 
a test session, 100 consecutive responses on either 
the sham or the ketamine-appropriate lever pro- 
duced food. Training and test sessions were con- 
ducted in alternation six days per week. If the 
performance criteria were not exhibited in a train- 
ing session (e.g., at least 90% correct responses in 
each trial), test sessions were not conducted until 
performance criteria were achieved in two con- 
secutive training sessions. 
At each dose of the test compounds, the data 
were calculated as the percentage of responses on 
the ketamine-appropriate lever. In addition, the 
rates of responding, irrespective of the lever on 
which the responses occurred, were calculated in 
responses/s .  
The drugs used in this study were ketamine 
hydrochloride (Warner-Lambert,  Ann Arbor, MI), 
phencyclidine hydrochloride (National Institute on 
Drug Abuse, Bethesda, MD NIDA),  l-(1-phenyl- 
cyclohexyl)-4-hydroxypiperidine hydrochloride, 4- 
phenyl-4-piperidinocyclohexanol (NIDA), and 1- 
[1-(4-hydroxylphenyl)-cyclohexyl]-piperidine hy- 
drochloride (Warner-Lambert).  
4-Phenyl-4-piperidinocyclohexanol was dissol- 
ved in sterile water to which a few drops of lactic 
acid were added and the pH of the final solution 
adjusted to above 4 with sodium hydroxide. All 
other drugs were dissolved in sterile 0.9% sodium 
chloride solution. Doses are expressed in the forms 
described above. 
3. Results 
The time course of the behavioral effects of 
ketamine (1.8 mg/kg ,  closed symbols) and PCP 
(0.18 mg/kg ,  open symbols) are shown in fig. 1. 
One min after their injection, both ketamine and 
PCP produced only saline-appropriate responding. 
After 5 min, an average of 62 and 72% ketamine- 
appropriate responding was produced by PCP and 
ketamine, respectively. Responding almost entirely 
on the ketamine-appropriate lever occurred at 10 
and 25 min following the administration of keta- 
mine. Ketamine-appropriate responding following 
PCP administration was 90% or greater at all time 
intervals between 25 and 90 min (upper panel 
fig. 1). The amount of ketamine-appropriate re- 
sponding produced by both drugs then decreased 
in a time-dependent manner until only sham-ap- 
propriate responding was observed 85 min after 
ketamine and 180 min after PCP administration 
(upper panel, fig. 1). Following ketamine, response 
rates were lowest at 5 min and had, subsequently, 
increased by 25 min; no large changes in response 
rates were observed at later time intervals (lower 
panel, fig. 1). The lowest response rate following 
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Fig. h Time course of the discriminative control of behavior 
exerted by the smallest doses of ketamine (1.8 mg/kg, closed 
symbols) and PCP (0.18 mg/kg, open symbols) that produced 
ketamine-like discriminative stimulus effects in each rhesus 
monkey (Solomon et al., 1982). Upper panel ordinates: re- 
sponses on ketamine lever, percent of total responses. Lower 
panel ordinates: response rate, responses/s. Abscissae: time 
after injection, min. The data are the mean of single observa- 
tions in each of three monkeys and were obtained in sessions 
that consisted of several discrete trials initiated at various times 
following drug injection; all trials, except the first trial of each 
experimental session, were preceded by a sham injection. Lines 
through the points indicate "- 1 S.E.M. 
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Fig. 2. Discriminative stimulus effects of PCP and three mono- 
hydroxylated PCP metabolites (upper panels) and the effects of 
these drugs on response rates (lower panels) in three rhesus 
monkeys. Ordinates: as in fig. 1. Abscissae: cumulative s.c. dose 
of drug, mg/kg. For PCP, each point represents the mean of 
three separate determinations in each animal. All other points 
represent data from a single determination in each animal. 
PCP occurred at 25 rain, after which these rates 
increased through 90 min and were then relatively 
constant  across later time intervals (lower panel, 
fig. 1). Thus, in compar ison  to ketamine, the dis- 
criminative control  of behavior  exerted by PCP 
and its effects on rates of responding were char- 
acterized by a somewhat  slower onset and a longer 
durat ion of action. 
The chemical structure of  PCP and three mono-  
hydroxyla ted  PCP metabolites and the discrimina- 
tive stimulus effects and rate-decreasing effects 
they produced are shown in fig. 2. In each monkey,  
PCP (closed hexagons) produced dose-related 
ketamine-appropr ia te  responding which reached a 
max imum at 0.3 m g / k g  (upper panels, fig. 2). Rates 
of  responding at the highest dose of  PCP were 
approximately  50% of those rates observed at lower 
doses (lower panels, fig. 2). In addition, p rofound 
ataxia, salivation, and nystagmus were noted in 
each animal following the sessions in which PCP 
was administered. 
The  m o n o h y d r o x y l a t e d  metabol i te  P C H P  
(closed triangles) also produced  dose-related 
ketamine-appropr ia te  responding in each animal. 
Responding on the ketamine-appropriate  key 
reached nearly 100% at 3 m g / k g  in two monkeys  
(794 and 808; upper  panels, fig. 2). In these 
animals, the rates of responding at the highest 
doses of  P C H P  were somewhat  decreased in com- 
parison to the response rates at smaller doses of 
the compound  (lower panels, fig. 2). In the third 
monkey  (754), the highest dose of  P C H P  evaluated 
(3 m g / k g )  produced nearly 40% ketamine-ap- 
propriate responding (upper panels, fig. 2). In this 
animal, no  large differences in the rates of  re- 
sponding were observed at the doses of P C H P  
evaluated. The effects of higher doses of P C H P  
could not be observed in this animal because the 
drug supply was exhausted. In all three animals, a 
syndrome of  PCP-like effects, including ataxia, 
salivation, and nystagmus, was observed at the 
conclusion of  these experimental sessions. 
In each monkey,  the monohydroxyla ted  metab- 
olite PPC (open circles) did not  produce responses 
on the ketamine-appropriate  lever over doses that 
ranged from 0.3 to 5.6 m g / k g  (upper panels, fig. 2). 
This compound,  however, markedly decreased the 
rates of responding at the highest doses in each 
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animal (lower panels, fig. 2). Ataxia, salivation, or 
nystagmus were not observed in any of the 
monkeys at the conclusion of these experimental 
sessions. 
Dose-related responding on the ketamine-ap- 
propriate lever reached nearly 100% at 3 mg /kg  of 
the monohydroxylated metabolite HPCP (closed 
circles) in each monkey (upper panels, fig. 2). Over 
the entire range of doses evaluated, the rates of 
responding were nearly constant in two of the 
monkeys (754 and 794, lower panels, fig. 2). Ataxia, 
salivation, and nystagmus were not observed in 
any of the animals following these sessions. Higher 
doses (10.0-17.8 mg/kg)  of HPCP, however, 
elicited these effects when evaluated in subsequent 
sessions. 
4. Discussion 
In the present experiment, the smallest doses of 
ketamine (1.8 mg/kg)  and PCP (0.18 mg/kg)  that 
produced ketamine-like discriminative effects 
(Solomon et al., unpublished observations) were 
evaluated with respect to the time course of these 
effects in rhesus monkeys. Ketamine had a slightly 
more rapid onset and a shorter duration of action 
than PCP. These results are consistent with the 
comparative time course of these drugs as dis- 
criminative stimuli in rats (e.g., Shannon, 1981) 
and as anesthetics in man (Domino et al., 1965). 
Reports that PCHP and PPC are inactive or 
that they exert only convulsant activity (McCarthy 
and Potter, 1963; Domino, 1964) are not sup- 
ported by the results of the present experiment. Of 
the three monohydroxylated PCP metabolites, 
PCHP and HPCP produced ketamine-like dis- 
criminative effects in the rhesus monkey and were 
approximately one-tenth as potent as PCP in this 
regard. Ketamine-like discriminative effects were 
not produced by PPC, although the compound 
was evaluated at doses up to and including those 
that markedly reduced rates of responding. None 
of the PCP metabolites produced observable con- 
vulsant activity in the present experiment. 
In general, the results of the present experiment 
agree with a report of the PCP-like discriminative 
effects produced by PCHP and PPC in rats (Shan- 
non, 1981). PCHP produced ketamine-appropriate 
responding in rhesus monkeys as well as PCP-ap- 
propriate responding in rats. It appears, however, 
that PCHP is slightly less potent relative to PCP in 
the monkey than in the rat, where only a three-fold 
potency difference was noted. On the other hand, 
there was at least a quantitative, and perhaps 
qualitative, difference between the effects of PPC 
observed in the present experiment and those re- 
ported in the rat. Whereas this compound pro- 
duced exclusively sham-appropriate responding in 
the present experiment, almost 65% drug-ap- 
propriate responding was observed at the highest 
dose of PPC tested in the PCP-trained rat (Shan- 
non, 1981). It would be interesting to train a 
discrimination based on PPC to examine its dis- 
criminative effects. 
In conclusion, the present results suggest that 
the behavioral effects of PCP, including the fre- 
quently observed long-lasting toxic psychosis (e,g., 
Luisada, 1978) may not be due to the effects of the 
three monohydroxylated metabolites evaluated in 
this study. One of these metabolites (PPC) pro- 
duced discriminative effects which were distinctly 
different from those produced by PCP in that 
response output was reduced by PPC without any 
significant drug-appropriate responding. Two other 
monohydroxylated metabolites (HPCP and PCHP) 
were similar to PCP in that they produced dose-re- 
lated ketamine-like discriminative stimulus effects, 
as well as a PCP-like syndrome characterized by 
ataxia, salivation, and nystagmus. Since these two 
metabolites were approximately one-tenth as 
potent as PCP, however, it is unlikely that they 
would be formed via biotransformation of PCP in 
amounts large enough to exert PCP-like behavioral 
effects. The results of the present investigation 
suggest that PCP is transformed to relatively inac- 
tive metabolites. This possibility is supported by 
the results of a previous report (Kalir et al., 1978) 
that, following the administration of [3H]PCP, the 
onset of behavioral effects was consistent with the 
time course of the distribution of radioactivity to 
the brain, whereas PCP-like behavioral effects di- 
minished more rapidly than the level of radioactiv- 
ity in the brain. 
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